ArticleScientific reports2026
Fecal sludge and adjacent drinking water as reservoirs of multidrug resistant ESBL-producing pathogenic Escherichia coli in Rohingya Camps, Bangladesh.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Fecal Sludge (FS) is a well-known reservoir for multiple pathogenic organisms and antimicrobial-resistant E. coli. Contaminated drinking water (DW) is the primary route through which fecal-oral diseases are spread. This study examined the prevalence of Extended-spectrum beta-lactamase (ESBL)-producing E. coli in FS and adjacent DW samples collected within the Rohingya Camps. The DW and treated FS samples were screened for thermotolerant E. coli and the isolates were characterized for their ESBL-production ability, presence of major antibiotic resistance (AMR) genes, pathogenic genes, biofilm formation ability and phylogenetic clustering. Among the samples, 88.1% FS and 40.2% DW contained E. coli. From the selected isolates, 32.3% of FS and 12.5% of DW were ESBL-positive. Subsequently, 113 ESBL-FS and 56 ESBL-DW isolates were characterized based on their concurrent presence. Upon screening, bla
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.